Neoepitope-based immunotherapies (Advaxis)

N/A

Report date: 2023/02/25 20:00:34

Base Information

Drug NameNeoepitope-based immunotherapies (Advaxis)
Drug Alias NameADXS-NEO
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsGene transference
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsCarcinoma, Transitional Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAyala Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAyala Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsCarcinoma, Transitional Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A